## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C07D 471/04

(11) International Publication Number:

WO 00/17199

(43) International Publication Date:

30 March 2000 (30.03.00)

(21) International Application Number:

PCT/EP99/07003

A1

(22) International Filing Date:

15 September 1999 (15.09.99)

(30) Priority Data:

9820405.0

18 September 1998 (18.09.98)

(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): HAYES, Jerome, Francis [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). WALSGROVE, Timothy, Charles [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). WELLS, Andrew, Stephen [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB).
- (74) Agent: BLAKEY, Alison, Jane; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### **Published**

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE (METHANESUL-FONATE SESQUIHYDRATE)

#### (57) Abstract

The present invention relates to an improved process for the production of the methanesulfonate sesquihydrate which comprises direct salt and hydrate formation. According to the invention there is provided a process for the production of 7-(3-aminomethyl -4-syn -methoxyiminopyrrolidin -1-yl)-1 -cyclopropyl -6-fluoro -4-oxo-1, 4-dihydro -1, 8-naphthyridine -3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl -4-syn -methoxyiminopyrrolidin -1-yl)-1 -cyclopropyl -6-fluoro -4-oxo-1, 4-dihydro -1, 8-naphthyridine -3-carboxylic acid of formula (I) having antibacterial activity and methanesulfonic acid in a solvent comprising at least onw water miscible cosolvent and water, and isolating the resulting solid product.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LÜ	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	•	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	ΚZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE (METHANESULFONATE SESQUIHYDRATE)

The present invention relates to a process for the production of a naphthyridine carboxylic acid derivative having antibacterial activity.

EP 688772 discloses novel naphthyridine carboxylic acid derivatives, including anhydrous (R,S)-7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of formula I, having antibacterial activity.

· 10

15

20

25

30

5

WO 98/42705 (published after the priority date of the present application) discloses (R,S)-7-(3-aminomethyl-4-syn-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof including the sesquihydrate (the "methanesulfonate sesquihydrate"). WO 98/42705 discloses a process for the production of the methanesulfonate sesquihydrate comprising reaction of the corresponding free base with methanesulfonic acid in dichloromethane / ethanol followed by recrystallisation of the resulting crude salt anhydrate from either water: acetone (10:7 v/v), or water: ethanol (1:2 v/v). The overall yield for this two step process is 70-80%. An alternative process for the production of the methanesulfonate sesquihydrate described in WO 98/42705 comprises exposing a solvate of the methanesulfonate (ethanol 0.11%) to high relative humidity (nitrogen >93% humidity).

The present invention relates to an improved process for the production of the methanesulfonate sesquihydrate which comprises direct salt and hydrate formation.

According to the invention there is provided a process for the production of 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and methanesulfonic acid in a solvent comprising at least one water miscible cosolvent and water, and isolating the resulting solid product.

The 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (hereinafter referred to as "the free base") used in the process of the invention may be prepared as described in EP 688772.

Water miscible cosolvents which may be used in the process of the invention include  $C_{1.8}$  alcohols, acetonitrile and dimethylformamide. The water miscible cosolvent is preferably a  $C_{1.4}$  alcohol or a mixture thereof, e.g. methanol, ethanol and propanol; the preferred  $C_{1.4}$  alcohol is isopropanol.

5

10

15

20

25

30

35

In addition to at least one water miscible cosolvent and water the solvent may contain other components, such as  $C_{1,4}$  haloalkanes. However, the solvent preferably comprises essentially of a water miscible cosolvent and water.

Suitable ratios of water miscible cosolvent: water for use in the process of the invention include ratios in the range 10:1 to 1:2 v/v, preferred ratios are in the range 10:1 to 1:1 v/v, more preferably a ratio of water miscible cosolvent: water of 2:1 v/v is used.

Any suitable ratio of free base to solvent may be used, for example, a ratio of up to 1:100 w/v, particularly a ratio of about 1:9 w/v.

The process of the invention may suitably use from 0.7 to >3 mole equivalents of methanesulfonic acid, preferably 0.7 to 1.5 equivalents, more preferably 0.9 to 1.5 equivalents, especially about 1.0 equivalent of methanesulfonic acid (based on the free base).

The mixture of the free base and methanesulfonic acid may be warmed in the solvent to aid dissolution. On cooling the methanesulfonate sesquihydrate will crystallise out of solution. To aid crystallisation the solution may be seeded with a small quantity of solid methanesulfonate sesquihydrate. In order to obtain polymorphically pure methanesulfonate sesquihydrate it is preferable that seeding of the solution is completed before crystallisation begins. Seeding of the crystallisation solution is preferably performed at a temperature ≥ 25°C, for example at a temperature of about 30°C.

The process of the invention may be used to produce racemic methanesulfonate sesquihydrate or may be used for the production of enantiomerically enriched or enantiomerically pure methanesulfonate sesquihydrate, using racemic or enantiomerically enriched or enantiomerically pure free base. Enantiomerically enriched or enantiomerically pure free base may be prepared by resolution of the racemic free base, e.g. by chiral HPLC.

The process according to the invention has the advantage that direct salt formation eliminates one step in the synthesis and gives a high yield of high purity methanesulfonate sesquihydrate. In turn these advantages result in improved throughput and savings in labour and materials costs during manufacture.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication

were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The invention is illustrated by the following example. However, it should be understood that the example is intended to illustrate but not in any manner limit the scope of the invention.

### Example 1: Preparation of the methanesulfonate sesquihydrate

5

10

15

20

To a suspension of (R,S)-7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (20.00 g, 51.4 mmol) in isopropanol (120 ml) and water (60 ml) was added methanesulfonic acid (3.300 ml, 50.9 mmol) at 38-40°C. The resultant dark brown solution was stirred for 15 min after which time charcoal (6.00 g of Darco G-60) was added. The suspension was stirred at 38-40°C for 4h then filtered. The filtrate was allows to cool to 30°C and seed crystals of (R,S)-7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate (15 mg) added. A precipitate began to form within 15 min. The suspension was allowed to cool to 20-23°C over 90 min and was stirred for 36h. The slurry was cooled to 0-5°C for 60 min then filtered and washed with isopropanol (50 ml and 44 ml). The product was sucked dry for 30 min and then further dried at 50-55°C under vacuum. The dried product was exposed to the atmosphere for 18h to give the methanesulfonate sesquihydrate 21.29 g (85%), purity >99.5% by HPLC.

The X-ray diffraction pattern of the methanesulfonate sesquihydrate was measured as follows:

	Diffractometer type:	PW1710 BASED
25	Tube anode:	Cu
	Generator tension [kV]:	40
	Generator current [mA]:	30
	Wavelength Alphal [Å]:	1.54060
	Wavelength Alpha2 [Å]:	1.54439
30	Intensity ratio (alpha1/alpha2):	0.500
	Divergence slit:	AUTOMATIC
	Irradiated length [mm]:	12
	Receiving slit:	0.1
	Spinner:	ON
35	Monochromator used:	YES
	Start angle [°20]:	3.500
	End angle [°2θ]:	35.000
	Step size [°20]:	0.020

Maximum intensity: 2970.250
Time per step [s]: 2.300
Type of scan: STEP
Minimum peak tip width: 0.10

Maximum peak tip width: 1.00
Peak base width: 2.00
Minimum significance: 0.50

The X-ray diffraction pattern of the methanesulfonate sesquihydrate is shown in Figure 1. The compound shows characteristic peaks at  $2\theta = 8.2$ , 12.2 and 14.6°.


#### **CLAIMS**

1. A process for the production of 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and methanesulfonic acid in a solvent comprising at least one least one water miscible cosolvent and water, and isolating the resulting solid product.

10

- 2. A process according to claim 1 wherein the water miscible cosolvent is a C<sub>1-4</sub> alcohol.
- 3. A process according to claim 2 wherein the water miscible cosolvent is isopropanol.
  - 4. A process according to any one of the preceding claims wherein the ratio of water miscible cosolvent: water is in the range 10:1 to 1:2 v/v.
- 20 5. A process according to claim 4 wherein the ratio of water miscible cosolvent: water is 2:1 v/v.
  - 6. A process according to any one of the preceding claims wherein the ratio of 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid: solvent is up to 1:100 w/v.
  - 7. A process according to any one of the preceding claims which uses from 0.7 to mole 1.5 equivalents of methanesulfonic acid.
- 30 8. A process according to any one of the preceding claims wherein the recrystallisation solution is seeded with 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate to aid crystallisation.
- 35 9. A process according to claim 8 wherein the solution is seeded whilst at a temperature of ≥ 25°C.
  - 10. A process according to claim 9 wherein the solution is seeded whilst at a

temperature of about 30°C.



Inter onal Application No PCT/EP 99/07003

			101/21 33/0/000	
A. CLASSIF IPC 7	FICATION OF SUBJECT MATTER C 07D471/04		•	
According to	international Patent Classification (IPC) or to both national classifica	tion and IPC		
	SEARCHED	ion and ii o		
	cumentation searched (classification system followed by classificatio C 0 7 D	n symbols)		
Documentati	ion searched other than minimum documentation to the extent that su	ch documents are incli	luded in the fields searched	
Electronic da	ata base consulted during the international search (name of data bas	e and, where practical	al, search terms used)	
C DOCUME	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No.	
Outegoly	Oldinoi di document, il more appropriate, oi me rec	Turn peoplege		
X	EP 0 688 772 A (LG CHEMICAL LIMIT 27 December 1995 (1995-12-27) cited in the application * see page 9, line 29-36 * the whole document	ED)	1-10	
Y	WO 96 39406 A (HANDANYAN LYNNE A PHILLIP J (US); MORRIS THOMAS A (12 December 1996 (1996-12-12) * see page 1, formula 1, and page preparation A * the whole document	ÚS); N)	1-10	
Υ	WO 91 02526 A (PFIZER) 7 March 1991 (1991-03-07) the whole document	/	1-10	
[V] 51/41	service and listed in the continuation of her C	Ratest family	members are listed in annex.	
<u> </u>	ner documents are listed in the continuation of box C.	L		
"A" docume conside "E" earlier of filing docume which citation "O" docume other m	ent defining the general state of the art which is not ered to be of particular relevance focument but published on or after the international ate in the which may throw doubts on priority claim(s) or is cited to establish the publication date of another or other special reason (as specified) and referring to an oral disclosure, use, exhibition or	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.		
later th	nan the priority date claimed	r of the same patent family		
	actual completion of the international search  1 January 2000	01/03/2	the international search report	
Name and n	nailing address of the ISA	Authorized officer	· · · · · · · · · · · · · · · · · · ·	
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Stellma	ach, J	

Inte onal Application No PCT/EP 99/07003

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Delayant to alain the
Category 3	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<i>(</i> .	EP 0 805 156 A (KYORIN SEIYAKU KK) 5 November 1997 (1997-11-05) the whole document	1-10
Y	EP 0 058 614 A (BELLON LABOR SA ROGER; DAINIPPON PHARMACEUTICAL CO (JP)) 25 August 1982 (1982-08-25) the whole document	1-10
Y	WO 97 36874 A (SMITHKLINE BEECHAM CORP; DUDDU SARMA (US); PALEPU NAGESWARA R (US)) 9 October 1997 (1997-10-09) the whole document	1-10
Y	WO 97 07098 A (PFIZER ;ANDINO MARTA M (US); SINAY TERRY G (US); FIESE EUGENE F (U) 27 February 1997 (1997-02-27) the whole document	1-10
Y	PATENT ABSTRACTS OF JAPAN vol. 015, no. 202 (C-0834), 23 May 1991 (1991-05-23) & JP 03 056479 A (TAKESHI YOKOTA), 12 March 1991 (1991-03-12) abstract	1-10
P,X	WO 98 42705 A (CHOI HOON ;KIM AE RI (KR); LEE JIN HWA (KR); LEE TAE HEE (KR); NAM) 1 October 1998 (1998-10-01) cited in the application the whole document	1-10
E	WO 99 61420 A (UPJOHN CO ;RUNGE THOMAS A (US)) 2 December 1999 (1999-12-02) the whole document	1-10

information on patent family members

Inte: onal Application No
PCT/EP 99/07003

	T		99/0/003
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0688772 A	27-12-1995	KR 131999 B CA 2151890 A,C CN 1114959 A DE 69509442 D DE 69509442 T JP 2742248 B JP 8041050 A US 5869670 A US 5962468 A US 5633262 A US 5698570 A	17-04-1998 17-12-1995 17-01-1996 10-06-1999 02-09-1999 22-04-1998 13-02-1996 09-02-1999 05-10-1999 27-05-1997 16-12-1997
WO 9639406 A	 12-12-1996	US 5840916 A US 5776944 A CA 2223404 A	24-11-1998 07-07-1998 
		HU 9601540 A AU 703634 B AU 5474996 A BG 100639 A BR 9602630 A CN 1148596 A CZ 9601625 A DE 69503066 D DE 69503066 T EP 0789697 A ES 2117426 T FI 974441 A HR 960267 A IL 118488 A JP 10506650 T LV 11619 A LV 11619 B NO 962321 A NZ 286735 A PL 314604 A SG 54339 A SI 9600185 A SK 71996 A US 5763454 A	28-02-1997 25-03-1999 19-12-1996 28-02-1997 08-09-1996 30-04-1997 16-09-1998 23-07-1998 15-10-1998 20-08-1997 01-08-1997 01-08-1997 31-08-1997 26-01-1999 30-06-1998 20-12-1996 20-04-1997 09-12-1996 16-11-1998 30-04-1997 05-03-1997 09-06-1998
WO 9102526 A	07-03-1991	AT 124040 T AU 623801 B AU 6104290 A CA 2023217 A,C CA 2127561 A CN 1049501 A,B CZ 9004027 A CY 1969 A DD 298399 A DE 69020262 D DE 69020262 T DK 413455 T EG 19251 A EP 0413455 A ES 2074131 T FI 964520 A GR 3017072 T HK 1000207 A	15-07-1995 21-05-1992 21-02-1991 17-02-1991 17-02-1991 27-02-1991 17-04-1996 05-09-1997 20-02-1992 27-07-1995 26-10-1995 14-08-1995 29-09-1994 20-02-1991 01-09-1995 11-11-1996 30-11-1995 06-02-1998

information on patent family members

Intel onal Application No
PCT/EP 99/07003

Patent docume cited in search re		Publication date		Patent family member(s)	Publication date
WO 9102526	·		IE IL JP	66202 B 95331 A 7149758 A	13-12-1995 31-07-1995 13-06-1995
			JP	8019099 B	28-02-1996
			JP	1975517 C	27-09-1995
			JP JP	3086875 A 7002734 B	11-04-1991 18-01-1995
			KR	9304844 B	09-06-1993
			LU	90310 A	25-01-1999
			LU	90311 A	25-01-1999
			NO NZ	300214 B 234920 A	28-04-1997 25-06-1992
			PL	166381 B	31-05-1995
			PT	94998 A,B	18-04-1991
			RU US	2049777 C 5266569 A	10-12-1995 30-11-1993
			US	5164402 A	17-11-1992
			US	5229396 A	20-07-1993
EP 0805156	5 A	05-11-1997	JP	8176143 A	09-07-1996
			AU AU	694946 B 3994695 A	06-08-1998 10-07-1996
			ÜS	5880283 A	09-03-1999
			CA	2208704 A	27-06-1996
			CŅ Hú	1171108 A 77945 A	21-01-1998 28-12-1998
			WO	9619472 A	27-06-1996
EP 0058614	1 A	25-08-1982	JP	1618494 C	12-09-1991
			JP JP	2043753 B 57134482 A	01-10-1990 19-08-1982
			AU	547082 B	03-10-1985
			AU	8017382 A	19-08-1982
			CA CS	1216292 A 8200998 A	06-01-1987 16-07-1987
			DD	202573 A	21-09-1983
			DK	63482 A,B,	14-08-1982
			ES FI	509538 A 820466 A,B,	01-08-1983 14-08-1982
			KR	8700322 B	27-02-1987
			MX	158194 A	16-01-1989
			NO PU	820430 A,B,	16-08-1982 12-04-1985
			PH PL	18177 A 235049 A	27-09-1982
			US	4442101 A	10-04-1984
			YU 7A	26582 A 8200740 A	30-04-1986 29-12-1982
			ZA		
WO 9736874	<b>4</b> A	09-10-1997	AU BR	2547097 A 9708336 A	22-10-1997 03-08-1999
			CN	1214682 A	21-04-1999
			CZ	9803101 A	17-03-1999
			EP No	0889880 A 984503 A	13-01-1999 28 <b>-</b> 09-1998
			110		
			NZ	332008 A	28-05-1999
				332008 A 329046 A 132298 A	28-05-1999 01-03-1999 10-03-1999

information on patent family members

Inter onal Application No
PCT/EP 99/07003

Patent document cited in search report			Publication date	Patent family member(s)			Publication date	
WO 9	9707098	A	27-02-1997	AU	710984	В	07-10-1999	
				AU	5908496	Α	12-03-1997	
				BG	102289	Α	30-09-1998	
				BR	9610766	Α	13-07-1999	
				CA	2228752	Α	27-02-1997	
				CN	1198739	Α	11-11-1998	
				CZ	9800390	Α	17-02-1999	
				EP	0843661	Α	27-05-1998	
				HR	960372	Α	30-04-1998	
				HU	9802862	Α	28-04-1999	
				JP	10510552	T	13-10-1998	
				NO	980574	Α	10-02-1998	
				NZ	309134	Α	29-09-1999	
				PL	325050	A	06-07-1998	
JP (	03056479	А	12-03-1991	NONE				
WO 9	 9842705	Α	01-10-1998	AU	6636698	A	20-10-1998	
		.,	11 10 100	NO	994595		21-09-1999	
WO 9	9961420	Α	02-12-1999	NONE				

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Потиер.

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.